FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050888916> ?p ?o ?g. }

• W2050888916 endingPage "303" @default.
• W2050888916 startingPage "296" @default.
• W2050888916 abstract "The Cilostazol Stroke Prevention Study 2 (CSPS 2) showed that cilostazol significantly reduced the risk of stroke by 25.7% relative to aspirin, with significantly fewer hemorrhagic events, in patients with prior ischemic stroke, excluding cardioembolic stroke. However, whether the benefit of cilostazol is sustained in patients with a high risk of bleeding has not been examined.We conducted a subanalysis of CSPS 2 to examine whether known risk factors for hemorrhagic stroke, such as stroke subtype and systolic blood pressure (SBP), influence the efficacy of the study drugs on hemorrhagic stroke. The relative risk reduction of hemorrhagic stroke was determined from the incidences calculated by the person-year method. The cumulative incidence rates of ischemic stroke and hemorrhagic stroke were estimated and plotted using the Kaplan-Meier method. Incidences of serious hemorrhage and hemorrhage requiring hospital admission were also evaluated in the two treatment groups. Hazard ratios (HR) and 95% confidence intervals (95% CI) calculated by the Cox proportion hazard model for cilostazol versus aspirin were assessed, and a log-rank test was used for the comparison between treatments.The incidence of hemorrhagic stroke was significantly lower in the cilostazol group than in the aspirin group among patients with prior lacunar stroke (0.36 vs. 1.20% in person-year, HR 0.35, 95% CI 0.18-0.70, p < 0.01), but not among those with prior atherothrombotic stroke (0.31 vs. 0.59% in person-year, HR 0.53, 95% CI 0.14-2.0, p = 0.34). The incidence of hemorrhagic stroke was significantly lower in the cilostazol group than in the aspirin group throughout all SBP categories (Poisson regression model including time-dependent covariates, p < 0.01) including SBP above 140 mm Hg (cilostazol 0.45% vs. aspirin 1.44% in person-year; Poisson regression model including time-dependent covariates, p = 0.02). Cilostazol, compared with aspirin, significantly reduced the incidence of cerebral hemorrhage (HR 0.36, 95% CI 0.19-0.70, p < 0.01), overall hemorrhage requiring hospital admission (HR 0.53, 95% CI 0.29-0.97, p = 0.04), and gastrointestinal (GI) bleeding requiring hospital admission (HR 0.44, 95% CI 0.21-0.90, p = 0.03).Hemorrhagic stroke was less frequent in the cilostazol group than in the aspirin group among patients with lacunar stroke as well as those with increased blood pressure levels. As for extracranial hemorrhage requiring hospitalization, GI bleeding was also less frequent in the cilostazol than in the aspirin group. Cilostazol is supposed to be a therapeutic option to replace aspirin for secondary stroke prevention, especially in these subgroups with high risks for hemorrhagic events." @default.
• W2050888916 created "2016-06-24" @default.
• W2050888916 creator A5003621363 @default.
• W2050888916 creator A5008787605 @default.
• W2050888916 creator A5009781138 @default.
• W2050888916 creator A5011453870 @default.
• W2050888916 creator A5021291521 @default.
• W2050888916 creator A5025141510 @default.
• W2050888916 creator A5032520963 @default.
• W2050888916 creator A5041888985 @default.
• W2050888916 creator A5044160830 @default.
• W2050888916 creator A5048319502 @default.
• W2050888916 creator A5055932126 @default.
• W2050888916 creator A5056872844 @default.
• W2050888916 creator A5058077031 @default.
• W2050888916 creator A5072475624 @default.
• W2050888916 creator A5078154299 @default.
• W2050888916 creator A5083128218 @default.
• W2050888916 creator A5090955736 @default.
• W2050888916 date "2014-01-01" @default.
• W2050888916 modified "2023-10-01" @default.
• W2050888916 title "Benefit of Cilostazol in Patients with High Risk of Bleeding: Subanalysis of Cilostazol Stroke Prevention Study 2" @default.
• W2050888916 cites W191849520 @default.
• W2050888916 cites W1964443629 @default.
• W2050888916 cites W1966268314 @default.
• W2050888916 cites W1971442835 @default.
• W2050888916 cites W1973915820 @default.
• W2050888916 cites W1988003366 @default.
• W2050888916 cites W2002526685 @default.
• W2050888916 cites W2024352468 @default.
• W2050888916 cites W2030673658 @default.
• W2050888916 cites W2030978243 @default.
• W2050888916 cites W2046301189 @default.
• W2050888916 cites W2054847084 @default.
• W2050888916 cites W2071335057 @default.
• W2050888916 cites W2071543617 @default.
• W2050888916 cites W2079056347 @default.
• W2050888916 cites W2086225625 @default.
• W2050888916 cites W2088653321 @default.
• W2050888916 cites W2099884864 @default.
• W2050888916 cites W2100089051 @default.
• W2050888916 cites W2107610682 @default.
• W2050888916 cites W2108656614 @default.
• W2050888916 cites W2127422554 @default.
• W2050888916 cites W2130615932 @default.
• W2050888916 cites W2163119611 @default.
• W2050888916 cites W2916753250 @default.
• W2050888916 doi "https://doi.org/10.1159/000360811" @default.
• W2050888916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24820203" @default.
• W2050888916 hasPublicationYear "2014" @default.
• W2050888916 type Work @default.
• W2050888916 sameAs 2050888916 @default.
• W2050888916 citedByCount "42" @default.
• W2050888916 countsByYear W20508889162014 @default.
• W2050888916 countsByYear W20508889162015 @default.
• W2050888916 countsByYear W20508889162016 @default.
• W2050888916 countsByYear W20508889162017 @default.
• W2050888916 countsByYear W20508889162018 @default.
• W2050888916 countsByYear W20508889162019 @default.
• W2050888916 countsByYear W20508889162020 @default.
• W2050888916 countsByYear W20508889162021 @default.
• W2050888916 countsByYear W20508889162022 @default.
• W2050888916 countsByYear W20508889162023 @default.
• W2050888916 crossrefType "journal-article" @default.
• W2050888916 hasAuthorship W2050888916A5003621363 @default.
• W2050888916 hasAuthorship W2050888916A5008787605 @default.
• W2050888916 hasAuthorship W2050888916A5009781138 @default.
• W2050888916 hasAuthorship W2050888916A5011453870 @default.
• W2050888916 hasAuthorship W2050888916A5021291521 @default.
• W2050888916 hasAuthorship W2050888916A5025141510 @default.
• W2050888916 hasAuthorship W2050888916A5032520963 @default.
• W2050888916 hasAuthorship W2050888916A5041888985 @default.
• W2050888916 hasAuthorship W2050888916A5044160830 @default.
• W2050888916 hasAuthorship W2050888916A5048319502 @default.
• W2050888916 hasAuthorship W2050888916A5055932126 @default.
• W2050888916 hasAuthorship W2050888916A5056872844 @default.
• W2050888916 hasAuthorship W2050888916A5058077031 @default.
• W2050888916 hasAuthorship W2050888916A5072475624 @default.
• W2050888916 hasAuthorship W2050888916A5078154299 @default.
• W2050888916 hasAuthorship W2050888916A5083128218 @default.
• W2050888916 hasAuthorship W2050888916A5090955736 @default.
• W2050888916 hasBestOaLocation W20508889161 @default.
• W2050888916 hasConcept C120665830 @default.
• W2050888916 hasConcept C121332964 @default.
• W2050888916 hasConcept C126322002 @default.
• W2050888916 hasConcept C127413603 @default.
• W2050888916 hasConcept C164705383 @default.
• W2050888916 hasConcept C207103383 @default.
• W2050888916 hasConcept C2777628954 @default.
• W2050888916 hasConcept C2779285336 @default.
• W2050888916 hasConcept C2779820409 @default.
• W2050888916 hasConcept C2780645631 @default.
• W2050888916 hasConcept C3020199598 @default.
• W2050888916 hasConcept C44249647 @default.
• W2050888916 hasConcept C50382708 @default.
• W2050888916 hasConcept C541997718 @default.
• W2050888916 hasConcept C61511704 @default.
• W2050888916 hasConcept C71924100 @default.

• next